AI-generated summary
The authors ran a controlled prospective trial of 308-nm XeCl-excimer laser treatment for vitiligo patches at different body sites in 24 patients who completed the study. They report that 67% of patients developed follicular repigmentation, with lesions on the face, trunk, arm, and leg responding earlier and more strongly than those on the elbow, wrist, hand, knee, and foot. Repigmentation was largely persistent 12 months after treatment ended.
- Participants
- 24
- Who or what was studied
- Patients with generalized or localized vitiligo (25 enrolled, 24 completed) with 85 lesions at different body sites
- Wavelengths
- 308 nm
- Limits stated in the abstract
- The abstract describes a relatively small trial of 24 completing patients and does not state a separate control group beyond untreated control lesions, so the findings may not generalize.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 308 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.